Mortality disparities among patients with HIV-associated Kaposi's sarcoma in the southern United States

被引:2
|
作者
Knights, Sheena M. [1 ,2 ]
Lazarte, Susana M. [1 ,2 ]
Kainthla, Radhika [2 ,3 ]
Chiao, Elizabeth Y. [4 ]
Nijhawan, Ank E. [1 ,2 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Div Infect Dis & Geog Med, Dallas, TX 75390 USA
[2] Parkland Hlth & Hosp Syst, Dallas, TX USA
[3] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Div Hematol Oncol, Dallas, TX 75390 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA
关键词
epidemiology; healthcare disparities; HIV; Kaposi's sarcoma; mortality; AIDS; EPIDEMIOLOGY; TRENDS; HERPESVIRUS; SURVIVAL; ERA;
D O I
10.1097/QAD.0000000000003155
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To describe risk factors for mortality in HIV-associated Kaposi's sarcoma in an urban population in Dallas, Texas. Design: Retrospective electronic medical record review of patients with HIV-associated Kaposi's sarcoma. Methods: Electronic medical records were reviewed from 1 January 2009 to 31 December 2018 for patients with a diagnosis of HIV and Kaposi's sarcoma by ICD-9 or ICD-10 codes. Demographics, HIV history, Kaposi's sarcoma history, treatment, and mortality data were collected. Mortality data was supplemented by an inquiry from the National Death Index (NDI). Survival analyses were performed using Cox proportional hazards analysis to determine independent predictors of mortality. Results: Black patients had higher mortality than white or Hispanic patients (hazard ratio 2.07, 95% confidence interval 1.12-3.82), even after adjusting for covariates. This mortality difference correlates with higher rates of advanced Kaposi's sarcoma disease and KS-IRIS in black patients compared with other groups and is not explained by differences in CD4(+) cell count, HIV viral load, engagement in care, or ART adherence at the time of cancer diagnosis. Conclusion: Despite nationwide trends showing decreased incidence and decreased mortality in Kaposi's sarcoma in the ART era, a high number of Kaposi's sarcoma cases and disparities in Kaposi's sarcoma outcomes persist in certain populations in the United States.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 50 条
  • [21] Racial disparities in incidence survival of Kaposi's sarcoma in the United States
    Kumar, Vivek
    Soni, Parita
    Garg, Mohit
    Hashmi, Arsalan Talib
    Chandra, Abhinav Binod
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2019, 149 (03): : 354 - 363
  • [22] Paclitaxel for relapsed or recurrent HIV-associated pediatric Kaposi's sarcoma
    Reddy-Holdcraft, Shoba
    Mehta, Parth S.
    Agrawal, Anurag K.
    [J]. AIDS, 2014, 28 (05) : 800 - 802
  • [23] Lack of association of low testosterone with HIV-associated Kaposi's sarcoma
    Falutz, J
    [J]. AIDS, 1996, 10 (07) : 794 - 795
  • [24] HIV TRANSCRIPTS DETECTED IN HIV-ASSOCIATED KAPOSI SARCOMA AND PSORIASIS
    MAHONEY, SE
    DUVIC, M
    NICKOLOFF, BJ
    LEWIS, DE
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 94 (04) : 552 - 552
  • [25] Evaluation of treatments for HIV-associated Kaposi sarcoma in Africa
    Krown, Susan E.
    Borok, Margaret Z.
    [J]. INFECTIOUS AGENTS AND CANCER, 2021, 16 (01)
  • [26] Oral HIV-associated Kaposi sarcoma: A case report
    Timofte, Adelina
    Rotaru, Georgiana
    Baderca, Flavia
    Vincze, Dana
    Solovan, Caius
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB55 - AB55
  • [27] Immunotherapy in HIV-associated Kaposi Sarcoma: Challenges and Prospects
    Tawana, Tiiso
    du Plessis, Julianne
    Omar, Aadilah
    [J]. CURRENT CANCER THERAPY REVIEWS, 2024,
  • [28] Evaluation of treatments for HIV-associated Kaposi sarcoma in Africa
    Susan E. Krown
    Margaret Z. Borok
    [J]. Infectious Agents and Cancer, 16
  • [29] High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma
    Ridolfo, AL
    Santambrogio, S
    Mainini, F
    Vago, L
    Gervasoni, C
    Gori, A
    Parravicini, C
    Monforte, AA
    Galli, M
    [J]. AIDS, 1996, 10 (02) : 181 - 185
  • [30] The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma
    Fumagalli, L
    Zucchetti, M
    Parisi, I
    Viganò, MG
    Zecca, B
    Careddu, A
    D'Incalci, M
    Lazzarin, A
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) : 495 - 501